Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing

Zydus Lifesciences has announced its entry into the global biologics CDMO market through the acquisition of Agenus Inc.'s (NASDAQ: AGEN) U.S.-based biologics manufacturing facilities for $75 million upfront, plus $50 million in contingent payments. The deal includes two state-of-the-art facilities in Emeryville and Berkeley, California, establishing Zydus's presence in a major biotech hub. As part of the agreement, Zydus will become the exclusive manufacturer for Agenus's Phase-3 ready immunotherapy products Botensilimab and Balstilimab. The acquisition positions Zydus as a comprehensive biologics solution provider and aims to capitalize on the growing biologics CDMO market, which is projected to reach $84.9 billion by 2034, with a CAGR of 15.7% from 2025-2034.

https://www.stocktitan.net/news/AGEN/zydus-to-enter-global-biologics-cdmo-business-plans-to-acquire-ae5plnicd6lk.html